If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Pharmaceutical firms saw mixed year in 2016

by Ann M. Thayer
December 5, 2016 | A version of this story appeared in Volume 94, Issue 48

Top 10 drug companies
Table of the top 10 drug companies of 2016.
Tough year for most European firms shuffled the ranking.
Note: Estimated sales are based on company statements and C&EN calculations.

Although overall sales expanded in 2016 for the top 10 drug companies, they were clearly split between those that grew and those that didn’t. With four of them seeing sales declines, the ranking got shuffled.

Fortunes were divided to some extent along geographic lines. Europe-based AstraZeneca, Novartis, and Sanofi all reported lower sales—the impact of patent expirations on their major small-molecule drugs.

In the near future, patent expirations will create competition for many top biologic products as well. But for now, Switzerland’s Roche posted higher sales on the strength of its biologics, as did AbbVie from its monoclonal antibody Humira. In contrast, reliance on the hepatitis C drug Harvoni, which had slowing sales, brought down Gilead Sciences’ numbers.

England-based GlaxoSmithKline had the biggest sales gains, but it came through prior business deals with Novartis in the vaccines and consumer health areas rather than improved sales of its medicines. Similarly, Pfizer’s rise in sales was largely the result of acquisitions.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.